Cell study · human keloid fibroblasts

FOXO4-DRI raised cell death in lab-grown keloid fibroblasts

Checked against the paper Cell studyPublished by PepVault

The takeaway

In lab models of keloid cells and tissue, FOXO4-DRI increased programmed cell death; this study did not test it in people with keloids.

Kind
Cell study
Studied in
Human keloid fibroblasts
Published
2025
Journal
Commun Biol

What they tested

The team wanted to know whether keloid scars hold many senescent (aged, non-dividing) fibroblasts, and whether the FOXO4-DRI peptide could push those cells to die.

How the study was done

A lab study of human keloid tissue and keloid fibroblasts (the cells that build scar tissue). It used single-cell RNA sequencing, protein tests, and pro-senescence models of keloid organ cultures and fibroblasts treated with FOXO4-DRI.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking FOXO4-DRI? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

Keloid samples had more senescent fibroblasts, more pro-inflammatory and mesenchymal fibroblast groups, more p16 protein and more beta-galactosidase-positive cells, all signs of senescence. They also had raised levels of p53 tagged with phosphate at serine 15 (p53-pS15). In the lab models of keloid fibroblasts and keloid organ cultures, FOXO4-DRI increased apoptosis, or programmed cell death, and left fewer cells in the G0/G1 phase of the cell cycle. At the same time, p53-pS15 moved out of the cell nucleus.

What it doesn’t show

This was lab work on keloid cells and tissue pieces, not a test in people or animals. It did not measure whether keloids shrink or come back less often.

The paper

Kong et al. FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation. Commun Biol. 2025.

The compound

More studies on FOXO4-DRI

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking FOXO4-DRI? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo